Exec Chat: Sequana Medical Pursues Dual Device-Drug Strategy For Fluid Overload
Executive Summary
Speaking to Medtech Insight, Sequana Medical’s CEO discussed the company’s two technologies for combating fluid overload whilst explaining that, sometimes, chasing approval as a drug can be the best way to ensure easy market access.
You may also be interested in...
Exec Chat: Catching Up With Drug-Device Developers Sequana At LSX
The company’s dual drug-device development pipeline is progressing well, with the company expecting its device, the Alfapump, to hit US clinics in 2025.
Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical
Sequana Medical is simultaneously developing both drug and device treatments for fluid overloads in the body. Medtech Insight spoke to the company’s CEO about their trials and the challenges of raising cash in 2023.
Pneumowave Breathes Easier In Its Fight Against Opioid Deaths After Completing £7.5m Raise
The Glasgow-based company has completed a large series A round to further develop its technology, which can be used to help save patients’ lives in the event of opioid overdose. Medtech Insight spoke to the Scottish National Investment Bank, one of the main investors, about the deal and its altruistic view of investment.